Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Open-Label Multicenter Trial to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

Next Previous
Trial Profile

A Phase 1/2 Open-Label Multicenter Trial to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; CFT 1946 (Primary) ; Trametinib (Primary)
  • Indications Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Thyroid cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors C4 Therapeutics

Most Recent Events

  • 13 May 2025 Status changed from recruiting to active, no longer recruiting.
  • 07 May 2025 Phase 1 dose escalation is complete with 640 mg BID declared as the maximum administered dose. Across the trial, which includes the dose escalation, melanoma and colorectal cancer cohorts, 89 patients were treated. The CFT1946 Phase 1 data will be presented at a future medical meeting.
  • 14 Jan 2025 According to a C4 Therapeutics media release, the company expects to complete monotherapy Phase 1 dose escalation in BRAF V600 mutant solid tumors in the first half of 2025, present Phase 1 data in the second half of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top